Medsenic amends licence agreement with Phebra for arsenic trioxide
30 May 2023
License out/inPhase 3
Preview
Source: Pharmaceutical Technology
Biotechnology company BioSenic’s affiliate Medsenic has amended its licence agreement with Australia-based pharmaceutical company Phebra for the oral formulation of arsenic trioxide (OATO).
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Benserazide Hydrochloride in Beta Thalassaemia GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Arsenic Trioxide in Myelodysplastic Syndrome GlobalData
View all
The formulation is intended for indications, including systemic sclerosis, graft versus host disease, systemic lupus erythematosus 151, central nervous system inflammatory diseases associated with multiple sclerosis and infectious diseases linked to Covid-19.
BioSenic chairman and CEO Professor François Rieger stated: “We are particularly satisfied with the excellent degree of coordination between Phebra and Medsenic, aimed at delivering the clinical batches for entering into the realisation of the expected Phase III trial of the oral medication, related to the previously agreed exclusive licence between Phebra and Medsenic.
“Both recent technical advances for the oral ATO clinical supply and the newly agreed amendment to the original licence will help render possible a quick FDA approval, through a necessary IND submission, followed by the expected activation of centres and patients recruitment.”
The licence agreement is contingent upon Medsenic’s ability to initiate a clinical study before 31 May 2024.
BioSenic Group and Phebra are also exploring the potential for extending Medsenic’s territories and related commercial terms.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.